跳至主要内容
临床试验/TCTR20210712003
TCTR20210712003尚未招募3 期

The study evaluating the efficacy, safety and economic evaluation of Thai medical marijuana products

Dr. Pongtorn Chantharatsami0 个研究点目标入组 668 人开始时间: 2021年7月12日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
668

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
25 Years 至 100 Years(—)
性别
All

入选标准

  • 1. Patient with metastatic cancer or incurable cancer whom was confirmed diagnosis by histology or radiology
  • 2. Patient who receives best supportive care, palliative care, or other non-curative therapy including: palliative chemotherapy, palliative radiation therapy, targeted therapy, hormonal therapy, and palliative surgery
  • 3. Patient who has symptoms or applies any medication in order to improve pain, nausea/vomiting, insomnia, or loss of appetite.
  • 4. age 25 years and older
  • 5. No previous medical marijuana administration at least 3 weeks prior to enrollment, if not, after stop medical marijuana at least 3 weeks, re-inclusion will be considered.
  • 6. PPS >= 40
  • 7. For female participants in reproductive age, urine pregnancy test must be negative and contraception must be consented prior to enrollment.
  • 8. For male participant, contraception must be consented and sperm donation during the study is not allowed.

排除标准

  • Patient who has the following:
  • 1. Continuing curative therapy, including: surgery, radiation, chemotherapy
  • 2. Severe symptoms of unstable cardio-pulmonary disease, including: angina, peripheral vascular disease, cerebrovascular disease, and arrhythmia
  • 3. History of psychosis, schizophrenia, or substance use disorder (alcohol, amphetamine, cocaine, except tobacco and caffeine)
  • 4. History of allergic reaction to medical marijuana product or its component
  • 5. Liver impairment including: cirrhosis, or elevated liver enzyme ( AST, ALT) more than 3 times of upper normal limit
  • 6. End-stage renal disease
  • 7. Pregnancy of breastfeeding woman
  • 8. Taking the following medication, which has drug interaction with marijuana: warfarin, rivaroxaban, apixaban, clopidogrel, cilostazol, phenytoin, carbamazepine, phenobarbital, perampanel, propranolol, metoprolol, bisoprolol, norfloxacin, ciprofloxacin, levofloxacin, amlodipine, nifedipine, and fluoxetine
  • 9. Not mindful or lack of capacity to answer questionnaires
  • 10. Can not communicate in Thai

研究者

发起方
Dr. Pongtorn Chantharatsami

相似试验